Alpha Tau Medical Ltd.
DRTSW
NASDAQ Global Market2.07
USD
-0.02
- -
CIK
0001871321
ISIN
IL0011839466
CUSIP
M0740A116
Return %
Stock
S&P500
1Y
777.12
24.99
3Y
446.03
70.19
5Y
204.46
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Uzi Sofer
- Full Time Employees
- 125
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building B3 Jerusalem Israel 9777605
- IPO Date
- Mar 8, 2022
- CIK
- 0001871321
- Website
- alphatau.com
- Similar Companies
- Business
- Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. The company's core product, Alpha DaRT, is an innovative alpha-radiation therapy technology that delivers highly potent and conformal radiation directly into tumors using intratumoral radioactive sources releasing short-lived alpha-emitting atoms. This focal treatment is designed to target solid tumors while sparing surrounding healthy tissues. Alpha Tau’s Alpha DaRT therapy is currently undergoing clinical trials for various cancers including skin cancer, oral cavity cancer, prostate cancer, pancreatic cancer, and breast cancer. The company focuses on difficult-to-treat tumors that are either localized and unresectable, metastatic, or have previously been treated with limited success using standard therapies. Alpha Tau operates primarily out of Jerusalem, Israel, where it is headquartered, and serves patient populations in the U.S. and other markets through clinical trials and strategic partnerships. In the last two years, Alpha Tau Medical has achieved significant milestones including receiving FDA approval for an Investigational Device Exemption (IDE) to initiate a pilot trial targeting patients with locally recurrent prostate cancer—marking the company's fifth active U.S. IDE trial. The company advances multiple parallel clinical programs, including a U.S. multi-center pilot study for pancreatic cancer treatments and ongoing recruitment for its pivotal ReSTART trial. To support commercialization readiness, Alpha Tau recently obtained a radioactive material license for a New Hampshire facility in the U.S. Additionally, in 2025, Alpha Tau entered into a strategic alliance and secured $36.9 million in funding from Oramed Pharmaceuticals. This partnership combines Oramed’s expertise in oral drug delivery and capital markets with Alpha Tau’s precision radiation technology, providing strategic marketing, capital raising support, and board representation to aid in clinical development, manufacturing scale-up, and eventual commercialization. Alpha Tau Medical was founded in 2003 following the development of the Alpha DaRT technology at Tel Aviv University. The company’s strategic focus includes extending the Alpha DaRT treatment’s applicability to solid tumors with high unmet medical needs such as pancreatic adenocarcinoma and glioblastoma, with the intention to combine the therapy with systemic treatments to boost its immunogenic effects and enhance outcomes against metastatic cancers. This positions Alpha Tau as a company at the forefront of innovative cancer therapies, leveraging a novel radiation approach to address patient populations with limited current treatment options. The company’s industry segment is clinical-stage biotechnology focused on oncology therapeutics, with its main offerings being its proprietary Alpha DaRT technology and associated treatment protocols to precisely deliver alpha radiation to solid tumors. Alpha Tau Medical’s target markets include oncologists, cancer centers, and patients facing localized, recurrent, or unresectable solid tumors primarily in the U.S. and Israel, while expanding clinical development globally. In summary, Alpha Tau Medical Ltd. is a Jerusalem-based oncology therapeutics company focused on alpha-radiation-based solid tumor treatments through its Alpha DaRT technology, currently advancing multiple clinical trials across key cancer indications, supported by recent FDA approvals, strategic funding, and partnerships aimed at accelerating commercialization and expanding treatment reach.
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.2% – Should You Sell?